Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
OTHER OTC:BCLI
Top Page
Brainstorm Cell Therapeutics
(OTC:BCLI)
Select Model
Select Model
Rating:40Underperform
Price Target:―
Brainstorm Cell Therapeutics' stock score is significantly impacted by its financial performance challenges, including ongoing losses and negative cash flows. While there are strategic advancements and partnerships aimed at derisking the regulatory pathway, the company's valuation and technical indicators reflect a bearish outlook. Investors should be cautious due to financial constraints and skepticism regarding the efficacy of its lead treatment, NurOwn.
Positive Factors
Regulatory Advancements
Securing a special protocol assessment with the FDA reduces regulatory risks, enhancing the potential for successful approval and commercialization of NurOwn.
Strategic Partnerships
Collaborations with IQVIA and Pluri Inc. strengthen trial execution and production capabilities, supporting efficient development and potential market entry of NurOwn.
Cost Reduction Achievements
Significant cost reductions in R&D and administrative expenses improve financial efficiency, aiding long-term sustainability and resource allocation for strategic initiatives.
Negative Factors
Financial Constraints
Ongoing net losses and reduced cash reserves highlight financial challenges, potentially limiting operational flexibility and investment in growth initiatives.
Delays in Phase 3b Trial
Delays in the Phase 3b trial initiation could postpone potential market entry and revenue generation, impacting long-term growth prospects.
Skepticism About Efficacy
Skepticism about NurOwn's efficacy requires robust clinical data to gain market and investor confidence, crucial for successful commercialization.
Brainstorm Cell Therapeutics (BCLI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.06M
Dividend YieldN/A
Average Volume (3M)22.93K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue GrowthN/A
EPS Growth47.54%
CountryUS
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding10,376,109
10 Day Avg. Volume25,343
30 Day Avg. Volume22,935
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue11.08
Enterprise Value/Gross Profit18.02
Enterprise Value/Ebitda-0.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Brainstorm Cell Therapeutics Business Overview & Revenue Model
Company DescriptionBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
How the Company Makes MoneyBrainstorm Cell Therapeutics generates revenue through the development and commercialization of its proprietary cellular therapies. The company's primary revenue stream is expected to come from the sale or licensing of NurOwn, pending regulatory approval and successful commercialization. Additionally, Brainstorm may engage in strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other stakeholders to advance its clinical programs and expand its market reach. These partnerships may provide upfront payments, milestone payments, and royalties, contributing to the company's earnings. Other potential revenue sources include government grants and funding from non-profit organizations that support research in neurodegenerative diseases.
Brainstorm Cell Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 17, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements towards clinical trials and strong community support, but these were overshadowed by financial challenges, NASDAQ delisting, and funding uncertainties. The sentiment is balanced between optimism for future trials and concern over current financial hurdles.Q2-2025 Updates
Positive Updates
FDA Clearance for Phase IIIb Trial
Brainstorm Cell Therapeutics received FDA clearance to initiate a pivotal Phase IIIb trial, ENDURANCE, for NurOwn in early-stage ALS patients. This provides regulatory clarity and strengthens the trial's foundation.
Manufacturing Partnership with Minaris
Secured a partnership with Minaris Advanced Therapies to enhance U.S.-based manufacturing capabilities for the upcoming clinical trial.
Support from ALS Community
A citizens petition was filed with the FDA by ALS patients and families, requesting a de novo review of NurOwn's data, showcasing strong community support.
Negative Updates
NASDAQ Delisting
Brainstorm's stock transitioned from NASDAQ to OTCQB due to noncompliance with NASDAQ's minimum shareholder equity requirement.
Increased Net Loss
Reported a net loss of $2.9 million for Q2 2025, compared to $2.5 million in Q2 2024, indicating financial challenges.
Funding Challenges for Clinical Trials
Inability to secure funding for the Phase IIIb trial and meet NASDAQ requirements due to regulatory uncertainties created by the citizens petition.
Company Guidance
During the Brainstorm Cell Therapeutics Second Quarter 2025 Conference Call, the company emphasized its commitment to advancing the NurOwn platform for ALS treatment through a planned Phase IIIb trial called ENDURANCE, following FDA clearance in May. The trial's design has been agreed upon with the FDA under a Special Protocol Assessment (SPA), aiming to support a future Biologics License Application (BLA). Financially, Brainstorm reported R&D expenditures of $1.1 million for the quarter ending June 30, 2025, up from $0.9 million in 2024, and a net loss of $2.9 million compared to $2.5 million the previous year. The company is actively seeking funding to initiate the trial and regain NASDAQ compliance, following a transition to the OTCQB. Additionally, a Citizens Petition has been filed with the FDA by ALS patients and families, advocating for a de novo review of NurOwn's data, which includes promising five-year survival statistics from an expanded access program.Brainstorm Cell Therapeutics Financial Statement Overview
Summary
Brainstorm Cell Therapeutics faces significant financial challenges, with ongoing losses and negative cash flows. Despite a slight improvement in equity, the company's financial stability is still at risk, requiring strategic changes to improve revenue and cash flow.Income Statement
Brainstorm Cell Therapeutics shows a significant net loss for multiple years with minimal revenue in 2024. The gross profit margin is 100% due to its small revenue covering costs, but net profit margins remain negative. The revenue growth rate is not meaningful due to zero revenue in previous years. Continued negative EBIT and EBITDA margins indicate ongoing operational challenges.25
Negative
Balance Sheet
The company has a fluctuating equity position, currently positive but previously negative. The debt-to-equity ratio is relatively low at 0.87, indicating some financial stability. However, the equity ratio is modest due to past negative equity, reflecting potential risk.30
Negative
Cash Flow
Operating cash flow remains negative, indicating insufficient cash generation from operations. Free cash flow is also negative, with a significant growth in free cash flow loss compared to past years. The operating cash flow to net income ratio is not meaningful due to consistent net losses.20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 849.00K | 849.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 522.00K | 849.00K | -265.00K | -285.00K | -260.00K | -219.00K |
| EBITDA | -11.68M | -11.31M | -16.93M | -23.99M | -24.28M | -31.46M |
| Net Income | -11.45M | 11.62M | -17.19M | -24.28M | -24.46M | -31.81M |
Balance Sheet | ||||||
| Total Assets | 2.57M | 1.83M | 4.21M | 8.45M | 29.28M | 51.26M |
| Cash, Cash Equivalents and Short-Term Investments | 824.00K | 187.00K | 1.30M | 2.98M | 22.09M | 41.94M |
| Total Debt | 577.00K | 720.00K | 672.00K | 4.09M | 5.08M | 7.22M |
| Total Liabilities | 8.62M | 9.60M | 9.07M | 11.47M | 9.94M | 15.79M |
| Stockholders Equity | -6.06M | -7.76M | -4.86M | -3.02M | 19.34M | 35.46M |
Cash Flow | ||||||
| Free Cash Flow | -9.48M | -9.09M | -20.48M | -19.35M | -26.59M | -35.57M |
| Operating Cash Flow | -9.48M | -9.09M | -20.46M | -19.32M | -26.27M | -35.19M |
| Investing Cash Flow | 12.00K | 12.00K | 2.19M | 998.00K | 323.00K | -4.45M |
| Financing Cash Flow | 6.84M | 7.97M | 18.98M | 238.00K | 6.97M | 76.94M |
Brainstorm Cell Therapeutics Technical Analysis
Negative
0.68
Price Trends
0.70
Negative
0.82
Negative
1.13
Negative
Market Momentum
>-0.01
Negative
47.12
Neutral
56.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCLI, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 0.69, below the 50-day MA of 0.70, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.12 is Neutral, neither overbought nor oversold. The STOCH value of 56.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCLI.
Brainstorm Cell Therapeutics Risk Analysis
Brainstorm Cell Therapeutics disclosed 64 risk factors in its most recent earnings report. Brainstorm Cell Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Brainstorm Cell Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
BCLI
Brainstorm Cell Therapeutics
0.68
-1.19
-63.64%
AIM
AIM ImmunoTech
2.38
-23.61
-90.84%
TCRT
Alaunos Therapeutics
2.72
0.67
32.68%
QLGN
Qualigen Therapeutics
2.86
-2.07
-41.99%
PMCB
PharmaCyte Biotech
0.96
-0.85
-46.96%
CYCN
Cyclerion Therapeutics
1.97
-0.92
-31.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.